Abstract:
Background. Glomerular nephropathies are a diverse group of kidney disorders, many
involving immune or inflammatory processes. Glucocorticoids are a mainstay of treatment
due to their powerful anti-inflammatory effects, but treatment response varies by subtype
and long-term use can cause serious side effects.
Objective(s). This thesis highlights the importance of personalized treatment by exploring
the mechanisms, indications, benefits, and limitations of glucocorticoid therapy in various
glomerular nephropathies.
Materials and methods. A literature review from 2013 to 2025 was conducted using
PubMed, Google Scholar, Medline, and other databases. Keywords included
“glucocorticoids,” “glomerulonephritis,” “nephropathy,” and diseases like “FSGS,” “IgA
nephropathy,” and “lupus nephritis.” Only English articles and clinical trials were included
to ensure quality and relevance.
Results. In minimal change disease (MCD), glucocorticoids induce remission in most cases,
especially in children. In focal segmental glomerulosclerosis (FSGS), efficacy is noted in
idiopathic cases but limited in genetic or maladaptive forms. IgA nephropathy and lupus
nephritis show favorable outcomes in proteinuria reduction and disease stabilization when
steroids are used judiciously. Conversely, membranous nephropathy and C3
glomerulopathy often require combination therapy. Resistance and adverse effects -
metabolic, psychiatric, and infectious - remain key challenges, often linked to receptor
polymorphisms and dosing issues.
Conclusion(s). Glucocorticoids are essential for treating glomerular nephropathies, but it’s
important to tailor the treatment to each patient’s specific disease type, severity, and overall
health. This personalized approach helps get the best
Results. s while reducing side effects and risks.
